Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.48 |
| ▸ | PGR | P06401 | 12/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16564526 | 0.88 | AR (0.46) | ARPGRNR3C2LMNACYP3A4 | |
| SCHEMBL3766911 | 0.87 | AR (0.51) | ARPGRNR3C2LMNACYP3A4 | |
| SCHEMBL13556644 | 0.83 | AR (0.52) | ARPGRNR3C2LMNACYP3A4 | |
| SCHEMBL3763087 | 0.80 | PGR (0.58) | ARPGRLMNACYP3A4CYP2C19 | |
| SCHEMBL923996 | 0.80 | AR (0.48) | ARPGRNR3C2LMNACYP3A4 | |
| SCHEMBL3359670 | 0.80 | PGR (0.58) | ARPGRLMNACYP3A4CYP2C19 | |
| SCHEMBL3354656 | 0.80 | PGR (0.58) | ARPGRLMNACYP3A4CYP2C19 | |
| SCHEMBL923848 | 0.80 | AR (0.48) | ARPGRNR3C2LMNACYP3A4 | |
| SCHEMBL10089125 | 0.79 | AR (0.55) | ARPGRNR3C2LMNACYP3A4 | |
| SCHEMBL3763186 | 0.78 | AR (0.60) | ARPGRNR3C2LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987239-B2 | 19-nor-steroid derivatives with a 15α,16α-methylene group and a saturated 17,17-spirolactone ring, use thereof, and medicaments containing said derivatives | Bayer Intellectual Property GbmH (DE) | 2015-03-24 | — | — | US | claimed |
| EP-2238149-B1 | 19-NOR-STEROID DERIVATIVES WITH A 15ALPHA, 16ALPHA-METHYLENE GROUP AND A SATURATED 17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | BAYER IP GMBH (DE) | 2015-03-18 | — | — | EP | claimed |
| US-20130123219-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15a,16a-METHYLENE GROUP AND A SATURATED 17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | claimed |
| US-20100311702-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15ALPHA, 16ALPHA-METHYLENE GROUP AND A SATURATED 17, 17-SPIRO-LACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | BAYER SCHERING PHARMA AKTEINGESELLSCHAFT (DE) | 2010-12-09 | — | — | US | claimed |
| US-8987239-B2 | 19-nor-steroid derivatives with a 15α,16α-methylene group and a saturated 17,17-spirolactone ring, use thereof, and medicaments containing said derivatives | Bayer Intellectual Property GbmH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20130123219-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15a,16a-METHYLENE GROUP AND A SATURATED 17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20100311702-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15ALPHA, 16ALPHA-METHYLENE GROUP AND A SATURATED 17, 17-SPIRO-LACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | BAYER SCHERING PHARMA AKTEINGESELLSCHAFT (DE) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311702-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15ALPHA, 16ALPHA-METHYLENE GROUP AND A SATURATED 17, 17-SPIRO-LACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | HSD17B7, CYP17A1, NR3C2 | AR 58/4885PGR 57/4885NR3C2 3/4885 |
| US-20130123219-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15a,16a-METHYLENE GROUP AND A SATURATED 17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | HSD17B7, CYP17A1, NR3C2 | AR 33/4885PGR 57/4885NR3C2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.